{
  "docId": "019de070-182a-72ba-952e-2b048c610e12",
  "docSlug": "cea7bfa85dc209a87c7b2adf6cd4697f",
  "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 22 slides",
  "authorId": "aeglea-biotherapeutics",
  "authorName": "Aeglea BioTherapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2020-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 11,
  "pageCount": 22,
  "prevPage": 10,
  "nextPage": 12,
  "slideType": "appendix_methodology",
  "function": "plan_implementation",
  "density": "dense",
  "nDataPoints": 5,
  "notes": "The slide outlines a randomized controlled trial structure with an open-label extension.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-182a-72ba-952e-2b048c610e12/11",
  "deckHref": "/decks/019de070-182a-72ba-952e-2b048c610e12",
  "deckJsonHref": "/decks/019de070-182a-72ba-952e-2b048c610e12.json",
  "deckAnchorHref": "/decks/019de070-182a-72ba-952e-2b048c610e12#slide-11",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.55,
        "x": 0.4,
        "y": 0.35
      },
      "kind": "diagram",
      "text": "Trial flow diagram showing patient selection, randomization (2:1), treatment arms (Pegzilarginase vs Placebo), and open-label extension.",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a1a18fd2-ce65-4b48-892c-0ed22532c307",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.35,
        "x": 0.05,
        "y": 0.33
      },
      "kind": "list",
      "text": "Primary: plasma arginine reduction\nSecondary: clinical responder endpoint\n- Timed Walk Test (2MWT)\n- GMFM-D (Standing)\n- GMFM-E (Walking, Running & Jumping)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "41f77936-c81b-4bb4-a741-327d4fd59c84",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.5,
        "x": 0.43,
        "y": 0.2
      },
      "kind": "paragraph",
      "text": "Single, Global Pivotal Phase 3 Trial Based on Input From FDA and EMA to Support Registration",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ee89623f-05bb-4995-b65a-0dab23ed41bf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.55,
        "x": 0.4,
        "y": 0.73
      },
      "kind": "source-note",
      "text": "*Dosing is weekly and, if needed, modified based on plasma arginine levels with maintenance of blinding. 'The first 8 weeks of the open-label extension will be blinded. All study participants remain on current disease management for the duration of the trial. ARG1-D = Arginase 1 Deficiency; IV = intravenous; R = randomized.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ab0fc563-3b77-4929-825f-b27d0407d81c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.04,
        "y": 0.06
      },
      "kind": "title",
      "text": "Pivotal Phase 3: PEACE Trial Design",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b69ef829-ecf0-4616-8438-70d968e7b60a",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "clinical-trial-design",
      "slug": null,
      "matchId": "7be793d1-05b5-4ee3-9797-a058d7a8b65d",
      "evidence": "Standardized representation of patient cohorts, randomization, and study phases.",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}